MV Biotherapeutics and Malcisbo agree to explore the Apyrase technology platform for AH Vaccines
Bellinzona – Schlieren, March 2021 MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the…